Refeyn, developer of pioneering mass photometry technology, announces the launch of the MyMass™ Mass Photometer (MyMassMP). This is a compact instrument designed to answer important research questions: “Is the sample of sufficient quality for further analysis?”
Structure-based drug design and AI-powered therapeutic development are transforming the way new drugs are discovered, but they require high-quality samples. Structural and biophysical workflows such as cryo-EM, native mass spectrometry (MS), biolayer interferometry (BLI), and surface plasmon resonance (SPR) are time-consuming and costly, and poor sample quality remains one of the main reasons for failure. MyMassMP allows researchers to quickly and accurately assess purity, homogeneity, and oligomerization status in solution before undertaking resource-intensive experiments.
MyMassMP is built on the same proven technology as Refeyn’s TwoMP mass photometer, already trusted by leading structural biology and biotherapy laboratories around the world, and brings this quality checking capability to a simpler, self-contained benchtop instrument. It features an integrated display and computer for onboard data analysis, and dedicated consumables, providing an intuitive sample-to-result workflow.
Structural biology and AI-driven drug discovery are rapidly advancing, but their success depends on the samples that drive them. MyMass directly addresses that challenge and represents a significant step forward for Refeyn, making the power of mass photometry available to more researchers than ever before. ”
Jerry McKay, Refeyn CEO
Fiona Coates, Chief Product and Marketing Officer at Refeyn, said: “In recent years, our users have consistently demonstrated how valuable mass photometry is for quickly assessing sample quality before embarking on more complex experiments. With MyMassMP, we are making this capability even more accessible, allowing researchers to confidently answer a simple but important question: Is the sample ready?”
